Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

869
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
869
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

1.1K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.1K
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

850
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
850
Stimulants01:29

Stimulants

1.1K
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
1.1K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

66
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
66
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The subjective effects of △9-tetrahydrocannabinol: A systematic review and dose-response meta-regression.

Neuroscience and biobehavioral reviews·2026
Same author

Changes in cannabis potency and cannabis-related psychiatric harms: a 23-year ecological study in Denmark.

Psychological medicine·2026
Same author

Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2025
Same author

The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis.

Systematic reviews·2025
Same author

Longitudinal evolution of the transdiagnostic prodrome to severe mental disorders: a dynamic temporal network analysis informed by natural language processing and electronic health records.

Molecular psychiatry·2025
Same author

Sub-clinical systemic inflammation as a determinant of admission duration in psychosis.

Schizophrenia research·2025
Same journal

Return on investment of enhanced primary youth mental health services in a large Canadian urban centre: a retrospective cohort study.

The lancet. Psychiatry·2026
Same journal

Correction to Lancet Psychiatry 2026; 13: 376-86.

The lancet. Psychiatry·2026
Same journal

Investing early in youth mental health: from promise to population evidence.

The lancet. Psychiatry·2026
Same journal

Navigating frameworks for translating mental health interventions from co-design to scale.

The lancet. Psychiatry·2026
Same journal

Interventions to support recovery of people with psychosis in low-income and middle-income countries: a systematic review.

The lancet. Psychiatry·2026
Same journal

Psychosis, human rights, and legal frameworks: global perspectives, with a focus on low-income and middle-income countries.

The lancet. Psychiatry·2026
See all related articles

Related Experiment Video

Updated: Mar 6, 2026

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

865

Can we make cannabis safer?

Amir Englund1, Tom P Freeman2, Robin M Murray1

  • 1Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

The Lancet. Psychiatry
|March 6, 2017
PubMed
Summary
This summary is machine-generated.

Higher potency cannabis, particularly delta-9-tetrahydrocannabinol (THC), increases risks like addiction and psychosis. Cannabidiol may reduce these harms, necessitating further research into cannabis risks and harm reduction strategies.

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.2K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.0K

Related Experiment Videos

Last Updated: Mar 6, 2026

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

865
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.2K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.0K

Area of Science:

  • Public Health
  • Neuroscience
  • Pharmacology

Background:

  • Global rise in cannabis use and potency necessitates harm reduction strategies.
  • Shift in legal stances from prohibition to decriminalization and legalization.
  • High delta-9-tetrahydrocannabinol (THC) cannabis is linked to increased risks.

Purpose of the Study:

  • To review studies on different cannabis types and their associated risks.
  • To explore how cannabidiol (CBD) may mitigate negative cannabis effects.
  • To inform future research for better understanding and reducing cannabis-related harm.

Main Methods:

  • Review of existing research on cannabis potency and effects.
  • Analysis of studies comparing high-THC cannabis with lower-THC varieties.
  • Examination of research on cannabidiol's (CBD) potential therapeutic and risk-mitigating properties.

Main Results:

  • Higher delta-9-tetrahydrocannabinol (THC) concentrations correlate with increased risks of addiction, psychosis, and cognitive impairment.
  • Cannabidiol (CBD), a non-intoxicating compound, shows potential in reducing adverse cannabis effects.
  • Variations in cannabis chemotype influence the nature and severity of associated harms.

Conclusions:

  • Understanding cannabis chemotype is critical for assessing and mitigating risks.
  • Cannabidiol (CBD) represents a promising avenue for harm reduction strategies.
  • Further research is needed to guide public health policies and interventions regarding evolving cannabis products.